TCT 2025: Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years, PARTNER-3 Trial Findings
This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA.
At seven years of follow-up, transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve demonstrated comparable clinical outcomes, valve durability, and survival to surgical aortic valve replacement (SAVR) in patients with severe symptomatic aortic stenosis (AS) at low surgical risk, according to findings from the PARTNER 3 trial presented by Dr. Leon at TCT 2025 and simultaneously published in The New England Journal of Medicine.
The PARTNER 3 trial, conducted across multiple international centers, is the largest randomized study comparing TAVR and SAVR in low-risk patients.
- The study enrolled 1,000 participants (mean age 73 years, 69% males) with severe symptomatic aortic stenosis and a Society of Thoracic Surgeons (STS) score below 4%.
Author's summary: TAVR shows comparable outcomes to SAVR at 7 years.
More News
- Windows 11 KB5067036 issue: Task Manager won’t close and duplicates, may hurt performance
- DWTS' Alan Bersten, Elaine Hendrix Taking 'It Easy' After Her Hospitalization
- This New Spy Thriller Series Took Over Netflix and Hit #3 Overnight
- Bruce Bruce County Museum marks Remembrance Day with special guest
- Astronaut Buzz Aldrin’s Wife Anca Faur Dead at Age 66
- Down 30% and Still Growing its Payout: 1 Canadian Stock I'd Snap Up
- Apple stock gets $320 target from BofA ahead of Q4 earnings - 9to5Mac
- Jimmy Butler issues “scary” warning to the rest of the NBA amid Warriors’ 4-1 start
- 'Down Cemetery Road' Release Schedule: When Are New Episodes Out?
- 'Selling Sunset' Star Chrishell Stause Calls Her Parents 'Bad *sses' After Fiery Confrontation With Nicole Young